Multiple Factors Determine the Oncolytic or Carcinogenic Effects of TLRs Activation in Cancer

Figure 9

TAK-242 inhibits oncogenesis. TAK-242 is a TLR4 antagonist that inhibits the binding of cell membrane TLR4 to its adaptor TIRAP or endosomal TLR4 to its adaptor TRAM. Such a blockade nullifies TLR4-TIRAP-MyD88 and the TLR4-TRAM-TRIF signaling. This results in a decrease in the production of proinflammatory cytokines. Consequently, inhibition of inflammation-associated cancer oncogenesis occurs.